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Abstract
Glutamine is the most abundant free amino acid in the human blood stream and is ‘conditionally essential’ to cells. Its
intracellular levels are regulated both by the uptake of extracellular glutamine via specific transport systems and by its
intracellular synthesis by glutamine synthetase (GS). Adding to the regulatory complexity, when extracellular glutamine is
reduced GS protein levels rise. Unfortunately, this excess GS can be maladaptive. GS overexpression is neurotoxic especially
if the cells are in a low-glutamine medium. Similarly, in low glutamine, the levels of multiple stress response proteins are
reduced rendering cells hypersensitive to H2O2, zinc salts and DNA damage. These altered responses may have particular
relevance to neurodegenerative diseases of aging. GS activity and glutamine levels are lower in the Alzheimer’s disease (AD)
brain, and a fraction of AD hippocampal neurons have dramatically increased GS levels compared with control subjects. We
validated the importance of these observations by showing that raising glutamine levels in the medium protects cultured
neuronal cells against the amyloid peptide, Ab. Further, a 10-day course of dietary glutamine supplementation reduced
inflammation-induced neuronal cell cycle activation, tau phosphorylation and ATM-activation in two different mouse
models of familial AD while raising the levels of two synaptic proteins, VAMP2 and synaptophysin. Together, our
observations suggest that healthy neuronal cells require both intracellular and extracellular glutamine, and that the
neuroprotective effects of glutamine supplementation may prove beneficial in the treatment of AD.
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Introduction
Glutamine is the most abundant free amino acid in the human
blood stream. It is typically classified as a ‘non-essential’ amino
acid because it can be made from TCA metabolites by most cells.
A more accurate classification of the body’s need for glutamine,
however, would be the term ‘conditionally essential’. Many cell
types are unable to survive in the complete absence of glutamine.
Indeed, in certain B-cell lines supranormal concentrations are
required. The value of glutamine is particularly apparent during
stress. It becomes essential in organs or organ systems weakened
by sickness, surgery or injury. Glutamine can regulate a variety of
target genes involved in cell proliferation, differentiation and
survival. It accomplishes this by altering the behavior of a range of
transcription factors, including NFkB, through which the anti-
inflammatory role of glutamine may be mediated [1]. A molecular
explanation for the broad cellular dependence on glutamine
remains elusive, but a key insight has emerged from recent studies
showing that high intracellular glutamine is rate limiting for the
uptake of several essential amino acids through the SLC7A5/
SLC3A2 bidirectional transporter [2].
In brain, the majority of endogenous glutamine is produced by
glutamine synthetase (GS), which catalyzes the formation of
glutamine from glutamate and ammonia. Although all cells
express GS to some extent, in the adult brain its levels are 40-
fold higher in astrocytes than in neurons [3,4,5]. In adult brains,
GS is neuroprotective [6,7] and during embryogenesis functional
GS is crucial for brain development. This can be seen from the
finding that congenital GS deficiency causes brain malformation
and neonatal death both in human and in mouse [8,9]. GS
responds to a variety of insults including oxidative stress,
inflammation, and viral infection [10,11,12,13,14], suggesting a
connection to neurodegenerative disease. Indeed, changes in GS
level, activity and modifications have been documented in AD
patients. Monomeric GS protein was found in 38 of 39
cerebrospinal fluid (CSF) samples obtained from AD patients
[15], and the concentration of GS is significantly increased in AD
CSF [16]. GS levels are also significantly higher in prefrontal
cortex of AD patients than they are in non-demented controls
[17]. Complicating the interpretation of these alterations in the
amount of GS protein, the activity of GS is vulnerable to mixed-
function oxidation which rises exponentially with age. Oxidized
GS has reduced activity and is preferentially degraded [18]. This
oxidation-induced loss of GS activity is brain region specific; it
happens at double the rate in frontal lobe compared to the
occipital lobe. Importantly, the decrease is more significant in
frontal cortex from AD patients than from age-matched controls
[19]. Proteomic analysis has identified GS as one of the cellular
proteins most prone to oxidation after Ab1–42 treatment in vitro
[20]. In vivo, GS is one of the 3 hippocampal proteins (along with
PIN1 and ENO1) that are found to be significantly oxidized in
both MCI and AD compared to controls [13]. The suggestion is
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compromised early in the Alzheimer’s disease process, the deficit
persists throughout the course of the disease, and perhaps like tau,
the quantities in CSF increase as the GS protein in brain cells
becomes increasingly dysfunctional.
In this study, we have explored the effect of glutamine and GS
supplementation on the survival of both N2a cells and primary
neurons. We compare the effects of altering endogenous glutamine
(through manipulations of intracellular GS and its activity) with
those found by altering the levels of exogenous glutamine. We
document an unexpectedly complex relationship suggesting that
both intracellular and extracellular glutamine are essential for
neuronal health. To make the link to neurodegenerative disease,
we extend these findings to the in vivo situation. We have used two
mouse models of AD to test the effect of dietary supplementation
of glutamine on the pathological features of the models. In the
aggregate, our data suggest that glutamine may have significant
neuroprotective effects that help restore homeostatic functions that
are lost in AD.
Materials and Methods
Ethics Statement
Human frozen tissues and formalin-fixed sections were obtained
from the Alzheimer’s Disease Research Center, Washington
University School of Medicine and the Alzheimer’s Disease
Research Center, Case Western Reserve University. Experimental
procedures involving these samples were approved by the
IRB of above two institutions and the Rutgers University
IRB. All animal procedures carried out in this study were in
accordance with Rutgers University IACUC standards, approval
ID: 06-027.
Human cases
Frozen brain tissues or formalin-fixed/paraffin-embedded
10 mm sections from AD and age-matched controls were obtained
from the Alzheimer’s Disease Research Centers at Case Western
Reserve University and Washington University School of
Medicine. Some of the cases used for this study had been clinically
diagnosed with AD and were subsequently confirmed with
standard pathological examination. Other cases died with no
explicit diagnosis of their dementia, but were scored on
neuropathological examinations as being either Braak stage V or
VI. For the purposes of this study, we defined these cases as AD.
Mouse strains
Two AD mouse models were examined [21] in this study. Both
carry the entire human APP gene inserted into the mouse genome
from a microinjected yeast artificial chromosome. Mice from the
R1.40 line (B6N129-Tg(APPSw)40Btla/J) carry the human APP
gene with the Swedish mutation for familial AD – K670N/
M671L. Mice from the 8.9 line (B6N129S2-Tg(APP)8.9Btla/J) are
similar to R1.40 animals but carry a wild type APP gene. Both
transgenic lines express all mRNA and protein isoforms of the
human gene in a correct spatiotemporal pattern.
Primary neuron and N2a cell cultures
Embryonic cortical neurons were isolated by standard proce-
dures. E16.5 embryonic cerebral cortices were treated with 0.25%
Trypsin-EDTA and dissociated into single cells by gentle
trituration. Cells were suspended in Neurobasal medium supple-
mented with B27 and 2 mM glutamine, then plated on coverslips
or dishes coated with poly-L-Lysine (0.05 mg/mL). All cultures
were grown for a minimum of 5 days in vitro (DIV) before any
treatment. Murine neuroblastoma N2a cells were purchased from
ATCC (Manassas, VA, USA) and cultured in standard DMEM
media supplemented with FBS (2% for differentiation, 10% for
routine passage) or Neurobasal+B27 with or without glutamine.
Synthetic amyloid-b peptide (Ab1–42) was purchased from
AnaSpec, Inc. (San Jose, CA). Peroxide oxidized Ab1–42 dimer
was prepared from synthetic human Ab1–42 (5 mM) by incubation
in PBS in the presence of hydrogen peroxide plus Cu2+ as
previously described [22].
Glutamine synthetase expression constructs and
transfection
An expression construct encoding human GS was purchased
from Origene (Cat# SC118847, pCMV6-XL5-GLUL, GenBank
accession No.: NM_002065). The disease-related mutation
(1021CRT) was introduced by means of site-directed mutagenesis
using the system developed by Mutagenex, Inc. The success of the
mutagenesis was confirmed by DNA sequencing using a GS
internal forward primer (Flk-F): 59-GACCCCTTCCGTAAG-
GACCC and a vector reverse primer (pCMV6 Seq-R): 59-
TTAGGACAAGGCTGGTGGGCAC. Sub-confluent N2a cells
were transfected with either Lipofectamine
TM 2000 or Lipofecta-
mine
TM LTX with PLUS
TM Reagent (Invitrogen) following the
manufacturer’s suggested procedure.
Western blotting and antibodies
For Western blots, protein extracts from tissues or cultures were
made in RIPA buffer with protease inhibitors and phosphatase
inhibitors, and then separated in 4–20% SDS–PAGE gel.
All antibodies used are commercially available. Antibodies
against GS, 53BP1, ATM, phospho-S1981-ATM (
PS1981-ATM),
cleaved caspase 6, LC3, LC3B,, PCNA, cyclin A, PSD-95 and
VAMP2 were all purchased from Abcam. Antibodies against




Cell Signaling. The Map2 antibody was purchased from Sigma.
Antibodies against cH2AX, Tau3R, Tau4R and phospho-tau
(AT8) antibodies are all mouse monoclonals purchased from
Millipore or Thermo. Synaptophysin antibody was from Invitro-
gen. b-actin antibodies were from Santa Cruz Biotechnology. Iba1
antibody was from Wako (Japan). The specificity of these
antibodies has been established previously and confirmed by us
through the use of Western blots.
Comet assay
The comet assay procedure was carried out using OxiSelect
TM
Comet Assay Kit from Cell Biolabs following the procedure
suggested by the manufacturer. Briefly, cultured cells were
detached from the culturing vessels by trypsinization. Cells were
then mounted in soft gels and electrophoresed for 15 minutes at
1 V/cm. After electrophoresis, slides were washed in water and
dried at room temperature. Finally, slides were stained with Vista
Green DNA dye (Cell Biolabs, Inc.) and visualized under a Leica
DM5000B fluorescent microscope or a Zeiss LSM 510 confocal
microscope using the FITC filter.
Immunohistochemistry and immunofluorescence
Each mouse was transcardially perfused with 4% paraformal-
dehyde under deep Avertin anesthesia, after which the brain was
dissected from the skull and post-fixed overnight. For most
material, the brain was embedded in paraffin and sectioned at
10 mm on a rotary microtome. The human materials were
formalin-fixed, paraffin-embedded and sectioned at 10 mm. These
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istry, all paraffin sections underwent antigen retrieval with high
temperature citrate buffer for 20 min, and then soaked in 0.3%
hydrogen peroxide to remove endogenous peroxidase activity.
Primary antibody was diluted in 10% goat serum with 0.5%
Tween-20. Primary antibodies were detected using biotinylated
goat anti-rabbit or anti-mouse secondary antibody (1:400), avidin-
biotin complex horseradish peroxidase and peroxidase substrates
including DAB, DAB+Ni and VIP (Vector Laboratories). Some
sections were counterstained with hematoxylin QS. For immuno-
fluorescence, mouse brains were embedded in OCT (Tissue-Tek)
and sectioned on a cryostat at 10 mm. Sections were pretreated
with citrate buffer for 10 minutes, and then incubated with
primary antibody. Alexa linked secondary antibodies were used to
detect the presence of the antigens. Stained sections were
photographed and viewed at a final magnification of 200 using
Leica Application Suite/Leica DM5000B.
LDH assay and MTT assay
For both LDH assay and MTT assay, cells were cultured in
media without phenol red. The LDH activity of the supernatant
was measured by Promega CytoTox 96H Non-Radioactive
Cytotoxicity Assay, according to the manufacturer’s instructions,
recording absorbance at 490 nm using absorbance at 650 nm as
reference. Cell viability (MTT assay) was evaluated using a
Promega CellTiter 96H Non-Radioactive Cell Proliferation Assay
kit following the manufacturer’s instructions, recording absor-
bance at 570 nm using absorbance at 650 nm as reference.
Results
Both endogenous and exogenous glutamine are
required for neuronal cell survival
Neurons take up exogenous glutamine as part of the glutamate/
glutamine cycle. Brain astrocytes clear glutamate from the synaptic
cleft, convert it glutamine and secrete it to the extracellular space.
Here it is picked up by neurons and converted back into glutamate
for use as a transmitter or used as a precursor for other cellular
components. Astrocytes typically maintain GS levels that are
readily visualized by immunocytochemistry; in neurons under
normal physiological conditions, GS is nearly undetectable. When
exogenous glutamine levels drop, however, neurons can be
induced to express GS [11]. Thus, although the levels of
exogenous glutamine can be easily regulated, the levels of
endogenous glutamine are a more complex function of uptake
plus the activity of GS.
We found that in cultures of primary cortical neurons, reduction
of exogenous glutamine had a small negative effect on neuronal
viability (Figure 1A, C; quantified in Figure 1E). As the full effects
of low media glutamine on the levels of intracellular glutamine
might be offset by GS-induced glutamine synthesis, we tested the
effects of the GS-inhibitor, methionine sulfoximine (MSO). MSO
is the best known inhibitor of GS. It was originally isolated from
nitrogenchloride-treated zein as the toxin responsible for the
induction of convulsions, hysteria and epileptic fits in a number of
animals (see reviews by Eisenberg et al. 2000) [24]. When added to
neuronal culture media in the presence of 2 mM glutamine, MSO
alone also caused the death of only a small number of neurons
(Figure 1B, E). By contrast, when MSO was added to cells grown
in glutamine-free medium (thus reducing both endogenous and
exogenous glutamine), massive neuronal cell death was observed
(Figure 1D, E). The reductions in exogenous and endogenous
glutamine were synergistic. In normal medium there is a baseline
level of caspase-3 labeling of about 7–8% of the total number of
cells. MSO alone increased the rate of cell death by ,3-fold;
glutamine removal from the medium alone increased cell death by
,2-fold. Applying MSO in the absence of glutamine, however,
increased cell death by ,8-fold. Thus, a healthy neuron requires
glutamine both in the media and synthesized internally by the
actions of GS.
GS induction in hippocampal neurons from AD patients
may be due to glutamine deprivation
In normal human hippocampus, astrocytes were the only cell
type with detectable levels of GS by immunocytochemistry
(Figure 2A). In AD patient samples, consistent with previous
reports [25], we found numerous hippocampal neurons with
elevated levels of GS (arrows, Figure 2A). Astrocyte staining was
not noticeably altered in these AD samples. The percentage of GS-
positive AD pyramidal neurons varied from subject to subject and
from region to region, ranging from 1–50% of the total
population. In the 4 control cases we examined, GS-positive
neurons were rare (,1%). We validated these findings by Western
blot using frozen brain samples from prefrontal cortex (Brodmann
area 9 – BA9) of 20 additional subjects (12 AD; 8 control). As with
the hippocampal immunohistochemistry, there was variability
among the samples. These blots clearly indicate, however, that GS
levels were elevated in frontal cortex of AD patients compared
with controls (Figure 2B). When these results were averaged across
all subjects, the increases in GS monomer and a higher molecular
weight species that is likely to be a GS dimer were both highly
significant (Figure 2C).
To verify that up-regulation of GS in neurons is triggered by
glutamine deprivation, we cultured mouse primary cortical
neurons (DIV 7–8) in Neurobasal media with or without
glutamine, in the presence or absence of 5 mM MSO, for 3 days
before collecting samples for Western blotting and immunocyto-
chemistry. In normal Neurobasal medium with 2 mM glutamine,
neurons express only trace amount of GS. As predicted by the in
vivo work, GS expression increased robustly when primary neurons
were deprived of glutamine either by removing exogenous
glutamine from the media (Figure 2D, lane 1) or by blocking
endogenous GS activity by MSO (Figure 2D, lane 4). The same
relationships were found in N2a cells, a murine neuroblastoma cell
line (Figure 2E).
Cellular response to GS levels varies in different
exogenous glutamine concentrations
Deprivation of exogenous glutamine can cause higher GS
expression in neurons. The question we next addressed was
whether this de novo expression of GS in neurons is protective or
detrimental. Our results further underscore the complex nature of
glutamine regulation in cells. We tested two GS constructs
expressing the human GS transcript 1: wild type GS (GS
WT)
and an activity-deficient mutant, GS
R341C. The GS
R341C construct
harbors a point mutation, R341C (a TRC change at nucleotide
1021 of human GS transcript 1), and encodes a peptide with
reduced GS activity [8]. N2a cells were transfected with either
construct or treated with only transfection reagents as a negative
control. After 24 hours, culture media were replaced with
differentiation media (Neurobasal without glutamine). After
another 24 hours, cells were treated with three different stressors
– 100 mMH 2O2, 100 nM oxidized Ab1–42 (oxyAb), or 5 mM
etoposide – for 24 hours in the same media. Then cells were
processed for Western blotting or immunocytochemistry. Exten-
sive degeneration of both processes and cell bodies was observed in
GS
WT but not GS
R341C -transfected cells (Figure 3A). The levels of
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with high GS activity (GS
WT transfection) than in cells expressing
the GS
R341C mutant (Figure 3B), even though comparable amount
of the two proteins were present. We repeated the transfections
using cells grown in medium containing 2 mM glutamine.
Intriguingly, with ample exogenous glutamine, high GS expression
reduced caspase-3 activity – as measured by the cleavage of key
cellular proteins such as retinoblastoma (RB, Figure 3C, D). To
directly evaluate cell death we treated N2a cells with H2O2 and
measured the lactate dehydrogenase (LDH) activity in culture
media, The LDH results confirmed the caspase 3 and caspase 6
data (Figure 3E). First, low glutamine increases cell death and
second, the difference between wild type and mutant GS is only
seen in low glutamine. Viewed together, our data point to the
conclusion that high levels of exogenous glutamine are highly
beneficial to neuronal cells whereas treatments that lead to high
GS activity may be useful only in certain conditions.
Multiple stress responses are compromised without
glutamine
The results in Figure 3 show that cells in low glutamine are
more sensitive to the effects of a variety of different stressors. To
explore this effect further, we treated N2a cells grown in normal or
reduced glutamine with H2O2 (1 mM – a model of oxidative
stress); ZnSO4 (0.2 mM – a model of heavy metal toxicity); and
etoposide (20 mM – a model of DNA damage). Cells were stressed
for 30 minutes then harvested for Western blot analysis. The
results in Figure 4A illustrate that cells grown in any medium can
respond to each of these conditions. They up-regulate their levels
of several stress response proteins such as 53BP1 and appropriately
modify other proteins either by phosphorylation (ATM) or
cleavage (caspase-3). The magnitude of all of these responses,
however, is considerably diminished in low glutamine. For
example, in all conditions, the levels of 53BP1 protein increased
in response to stress. In low glutamine, however, the final levels of
Figure 1. Deprivation of exogenous and endogenous glutamine synergistically promotes neuronal cell death. A–D) Primary neurons
were grown in four different culture media. A) normal; B) normal glutamine in the presence of the glutamine synthetase (GS) inhibitor, methionine
sulfoxide (MSO); C) glutamine-free; D) glutamine-free plus MSO. After 2–3 days cells were immunostained for Map2 (red) and cleaved caspase-3
(green), pictures were taken at a magnification of 2006. E) Cell counts reveal the ratio of apoptotic neurons (Caspase-3-stained) to total cell counts
(DAPI staining). Error bars correspond to standard deviations; * denotes p,0.05, ** denotes p,0.01.
doi:10.1371/journal.pone.0033177.g001
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Activation of ATM and ATR by phosphorylation revealed a
similar picture. Under oxidative stress or etoposide-induced DNA
damage, the activating phosphorylation of both proteins increased.
Etoposide treatment drove robust ATM auto-phosphorylation,
this change in phosphorylation led to an actual change in ATM
kinase activity can be seen in the increased levels of cH2AX, while
the phosphorylation of ATR was driven preferentially by ZnSO4.
For each of these measures of stress response, however, the
magnitude of the response in low glutamine was significantly less
than in normal exogenous glutamine. One likely reason for this
difference is that the levels of total ATM and total 53BP1 are
reduced in low glutamine (Figure 4A–B). Viewed as a whole, the
data in Figure 4A suggest that in many different domains, cells in
low glutamine are not well prepared for stress.
We presumed that the findings in Figure 4A reflected the
reduced levels of the various damage response proteins. This
assumes, however, that the levels of damage induced by the
various stressors are equivalent in low glutamine. To address this
concern, we examined the response of the cells to etoposide since
DNA damage can be easily monitored by Comet assay. In the
absence of etoposide, DNA damage is minimal, even in low
glutamine (Figure 4C). After 30 min in 5 mM etoposide, DNA
fragmentation is easily revealed by the appearance of significant
comet tails (top row, Figure 4C). We then removed the etoposide
and followed the cells’ ability to repair their DNA. Within 4 hours,
the Comet tails found on cells in both culture conditions
disappeared, indicating the cells were able to join the majority
of their DNA breaks, with or without glutamine (Figure 4C). Yet
while the DNA might have been ‘‘repaired’’ in both situations,
there was significantly more cell death in the glutamine-deprived
cultures as assessed by the number of pycnotic nuclei (Figure 4D).
The majority of this death is likely necrosis not apoptosis because
markers of apoptosis (activated caspase-3) and autophagy (LC3-II)
were higher in cultures with glutamine than in those without
glutamine (Figure 4A, B). To directly evaluate cell death and
viability, we also performed LDH assay after a 6 hour recovery
(Figure 4E) and MTT assay after a 24 hour recovery (Figure 4F)
from a 30 minutes H2O2 challenge. Collectively, glutamine is
essential for the stress response and post damage survival of cells.
Cells in low glutamine are more sensitive to the
neurotoxic effects of Ab
N2a cells grown in low glutamine are sensitive to toxic effect of
DNA damage and oxidative stress, likely due to low expression of
stress response proteins such as ATM and 53BP1(Figure 4A–B).
However, this impaired response capability is not unique to the
N2a cells; similar reductions of ATM, ATR and 53BP1 are
Figure 2. Glutamine deprivation up-regulates GS expression. A) GS immune-positive hippocampal neurons were detected in AD patients but
not in control samples. Immunopositive astrocytes are found in both. B) GS levels in AD frontal cortex are significantly higher than in control samples.
One representative blot at two different exposure times is shown. C) Quantification and statistics of 12 AD and 8 control cases. GS levels in controls
were arbitrarily set as 100%. Error bars denote standard deviations. P values were calculated via Student’s T-test. D) Removing glutamine from culture
medium or inhibiting GS activity with MSO induces GS expression in primary neurons. E) Removing glutamine from the culture medium promotes GS
expression in N2a cells.
doi:10.1371/journal.pone.0033177.g002
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Like N2a cells, neurons grown in low glutamine were more
sensitive to DNA damage as well (Figure 5B). The importance of
glutamine to the survival of neuronal cells prompted us to examine
the effect of glutamine supplement on Ab-induced toxicity.
Primary neurons were cultured in medium with 2 mM glutamine
(replaced every 2–3 days) until DIV 10–15. Cells were then re-fed
with fresh medium with or without glutamine. Twenty-four hours
later, the cells were treated with 100 nM oxyAb for additional
24 hours; oxyAb has been shown to more readily form neurotoxic
oligomers and is more potent than un-oxidized Ab in its ability to
induce cellular stress in neurons [22]. We monitored the neuronal
response using the AT8 phospho-tau antibody. Although oxyAb
induced tau phosphorylation in cultures with or without
glutamine, the levels of phospho-tau were significantly reduced
in the presence glutamine (Figure 5C). The effects of glutamine
were dose dependent as can be seen from the effects on tau
phosphorylation (Figure 5D). Even neurons in long-term estab-
lished cultures responded to 3 days of glutamine deprivation and
Ab treatment by showing more processes beading (Figure 5E) and
less synaptophysin staining (Figure 5F) suggesting reduced synaptic
density.
Glutamine supplementation appears to protect neurons
in vivo
These in vitro findings provide multiple pieces of evidence that
under conditions of neuronal stress such as is found in
neurodegenerative disease, glutamine might have significant
clinical value. The Ab results further suggest that Alzheimer’s
disease might be a prime candidate for intervention. To test this
concept in a preclinical disease model, we examined the effects of
dietary glutamine on the phenotypes of the R1.40 and 8.9
transgenic mouse strains. Both lines carry an entire genomic copy
of the region of human chromosome 21 with the APP gene [21].
The R1.40, mice develop amyloid plaques by 13 months (on a
C57BL/6J background); 8.9 mice remain plaque-free throughout
their lives on this background. Both lines develop neuronal cell
cycle events in brain regions homologous to those affected in
humans [26,27]. These cell cycle events are robust outcome
measures that are useful in tracking impending neurodegenerative
Figure 3. Overexpression of GS enhances neurodegeneration in the absence of exogenous glutamine. A) GS overexpression causes the
degeneration of processes in differentiated N2a cells, while the low activity mutant GS
R341C appears to have no same effect. B) Both wild type and
mutant GS overexpression increases the levels of apoptotic markers (cleavage of caspase-3 and caspase-6) in basal conditions and under stress tested
including 0.1 mM H2O2, 100 nM Ab and 20 mM etoposide. Mutant GS
R341C had consistently less effect than GS
WT. C) Western blot shows the effects of
GS overexpression in the presence or absence of free glutamine in the culture medium. The phospho-RB antibody provides evidence of both
enhanced cell cycle (increased full length P-Rb) and cell death (caspase-3-cleaved Rb, P-Rb*) simultaneously. D) Quantification of 4 repetitions of the
experiment illustrated in panel C. Error bars denotes standard deviations. *=p,0.05; **=p,0.01 (by Student’s T-test). E) Cell death evaluated by LDH
assay. N2a cells overexpressing wild type GS and GS(R341C) were treated with 1 mM H2O2 for 30 minutes then allowed to recover in fresh media with
or without glutamine for 6 hours before LDH assay. Error bars denote standard deviations. *=p,0.05.
doi:10.1371/journal.pone.0033177.g003
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they can be prevented by NSAID treatment or advanced by an
additional immune challenge such as LPS injection [28]. Given
that LPS infusion in healthy human subjects causes a dramatic
depletion of glutamine from their brains [29], we speculated
glutamine may have a significant effect on LPS-treated R1.40 and
8.9 mice.
One-year-old R1.40 and APP8.9 mice were fed 4% glutamine
in their drinking water for 10 days. The following day they were
injected with a low dose of LPS to induce systemic inflammation
[28], and sacrificed 2 days later for analysis. Control mice were
treated the same way except that they were kept on regular
drinking water. We had 3 mice in the glutamine supplement group
and 4 mice in the control group. We did extensive comparison of
all the markers we used and found no differences between APP8.9
and R1.40. The only exception was the transgene encoded APP;
R1.40 mice had higher APP expression than APP8.9 mice, as
expected. Instead, we found a significant difference between mice
with or without glutamine in their drinking water. As expected, in
mice fed with normal drinking water (Gln2), LPS treatment was
Figure 4. Stress responses are compromised without glutamine. A) N2a cells were treated with different cellular stressors for 30 minutes, and
then collected and analyzed on Western blots. The various stress response proteins are indicated at the right and are described in more detail in the
text. P-ATM=
PS1981-ATM. B) N2a cells were treated with 5 mM etoposide for 30 minutes to induce DNA damage. Etoposide was removed and fresh
medium with or without glutamine was added. Cells were collected at indicated time points for Western blot analysis. Gln2=glutamine-free
medium; Gln+=2 mM glutamine containing medium. C) Comet assays were performed on a portion of the samples collected for experiments shown
in panel B. In each panel, the arrowhead points to a representative cell that is shown at higher magnification in the inset. There are few comet tails in
control cultures. After 30 min in etoposide, however, the typical cell had well developed comet tails indicative of DNA damage. After 4 hours
recovery, most comet tails disappeared in cultures with or without glutamine, but more pycnotic nuclei are found in glutamine deprived cultures. D)
Counts of pycnotic nuclei as a measure of cell death. For each condition, 250 randomly selected cells were examined under a microscope; cells were
separated into four categories: normal nucleus, blebbing nucleus, condensing nucleus, and disappearance of nuclear material. E) Cell death evaluated
by LDH assay. N2a cells treated with 1 mM H2O2 for 30 minutes, and allowed to recover in fresh media for 6 hours. LDH activity was measured by the
reactions absorbance at 490 nM, using absorbance at 650 nm as a reference. ** denotes p,0.01, error bars=standard deviation. F) Cell viability
evaluated by MTT assay. Cells were treated as E, but allowed to recover for 24 hours before MTT assay (absorbance at 570 nm, reference at 650 nm).
** denotes p,0.01, error bars=standard deviation.
doi:10.1371/journal.pone.0033177.g004
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thickening and shortening of their Iba-1-stained processes
(Figure 6A). In mice supplemented with glutamine, however,
LPS failed to induce activation. Microglia in these mice (Gln+)
showed the normal resting phenotype with thin and long Iba-1-
positive processes. Glutamine supplementation also led to a
reduced level of tau phosphorylation, as well as ATM phosphor-
ylation (Figure 6B–C). The expression of the cell cycle maker,
PCNA (Figure 6B–C) was also reduced with glutamine supple-
mentation. Immunostaining using cyclin A antibody corroborated
the PCNA results (Figure 6D, arrows). VAMP2, one of the
synaptic vesicle SNARE proteins that is reduced both in AD
models and in AD patients [29], was restored by glutamine
supplementation, as was synaptophysin (Figure 6B–C). The levels
of PSD95, however, remained unchanged. Thus, a 10-day
regimen of glutamine supplementation was sufficient to block
the expression of several indices of neurodegenerative disease in
two AD mouse models.
Discussion
Our data provide strong support for a neuroprotective effect of
glutamine supplementation in a variety of different situations. The
molecular nature of this protection is complex and reflects the
Figure 5. Neurons in low glutamine are more sensitive to the neurotoxic effect of Ab. A) ATR levels are significantly reduced in neurons
cultured without glutamine. ATM and 53BP1 are reduced by a similar amount, but the variability in the assay kept these change at the level of a trend
rather than a significant difference. Average of 3 repeat experiments; error bar denotes standard deviation, *=p,0.05. B) Neurons grown for 9 days
(DIV9) in Neurobasal medium with or without glutamine were treated with 20 mM etoposide for 30 minutes, then immunostained for activated
caspase 6 staining (green) and counterstained with DAPI (blue). C) Ab-induced tau phosphorylation in primary neurons depends on glutamine status
in the culture medium. D) Tau phosphorylation is suppressed by glutamine in a concentration-dependent manner, even though levels of total tau
(3R) remain unchanged. E) Aged neurons treated with Ab have more processes degeneration (beaded Map2 stained dendrites) in the absence of
glutamine. F) Synaptophysin staining is increased in the presence of glutamine. The numbers in each panel refer to the concentration of glutamine
(mM) in the culture medium.
doi:10.1371/journal.pone.0033177.g005
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state of oxidation of the synthetic enzyme, glutamine synthetase
(GS).
Neurons in normal situations express little GS, but when
exogenous levels of glutamine fall, we find that neuronal GS
expression increases significantly. This is consistent with repeated
observations that the activity of GS is regulated by cumulative
feedback inhibition and is dictated by the overall cellular demand
for glutamine [30]. It is also consistent with the finding that
patients with congenital glutamine deficiency resulting from GS
mutations (R324C and R341C) have much higher expression of
GS message than either their parents or normal controls [8]. As
the specific activity of R324C and R341C is reduced from wild
type, the suggestion is that GS activity, rather than protein
concentration, is the attribute that regulates the level of GS
transcription.
These observations have direct relevance for neurodegenerative
disease as reduced glutamine/glutamate levels have been reported
in the AD brain [31,32,33]. As might be predicted, in regions
affected by AD pathology, many neurons are found to express
abnormally high levels of GS (e.g., Figure 2A and earlier reports
[25,34]). Manipulating GS levels, however, carries risk as a
therapeutic target. While, increasing GS might help to raise
intracellular glutamine, in an environment of low exogenous
glutamine degeneration is induced (Figure 3). Further, the
complex chemistry of the AD brain worsens the situation since
increased levels of catalytically active GS renders a cell
hypersensitive to the toxic effects of Ab and other stressors, an
outcome to be avoided in AD.
Manipulation of glutamine itself would seem to have fewer such
risks. In addition to the direct neuroprotective effects, there is a
significant anti-inflammatory action of glutamine supplementation
(Figure 6A). Perhaps because the immune system must overcome
this effect to be fully reactive, the pro-inflammatory cytokine,
TNFa, has been shown to reduce GS expression in astrocytes [10].
This would be consistent with observations that systemic
inflammation induced by LPS injections in human volunteers
reduces the glutamine pool in brain [35]. Chronic inflammation
Figure 6. Glutamine supplementation protects neurons in AD mouse models in vivo. R1.40 and 8.9 mouse models of AD were treated with
LPS as an immune challenge to enhance the degenerative phenotype. A) Microglia activation is dampened in mice supplemented with glutamine.
Two different brain regions are shown as indicated at the top of each column. Microglia was stained with Iba-1 antibody. Activated microglia has
thicker and shorter processes compared to resting microglia. B) Western blots show protective effect of glutamine supplementation (Gln+): lower tau
phosphorylation (AT8), less cell cycle reentry (PCNA), less ATM activation (P-ATM) and more expression of synaptic maintenance proteins (VAMP2 and
synaptophysin).C) Western blots shown in panel B were quantified and analyzed for statistical significance between control and glutamine
supplementation, * denotes p,0.05. D) Immunofluorescent images show less cyclin A staining in cortical neurons of animals supplemented with
glutamine.
doi:10.1371/journal.pone.0033177.g006
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features of AD [36]. These data suggest, therefore that glutamine
supplementation may be beneficial to AD patients as it should be
anti-inflammatory in the brain. In addition, it would appear that
glutamine supplementation improves the DNA damage response
(Figure 4). This may well explain the success of glutamine
supplementation in mitigating the harmful side effects of
radiotherapy for various cancers [37,38]. This effect also has
relevance for late-onset diseases such as AD as it has been argued
that DNA damage is a direct cause of aging [39]. The cellular
DNA damage response system is a complex network of proteins
that protect cells by either fixing the damage or forcing cells into
apoptosis or senescence. If the repair process is blocked, however,
some DNA will stay unrepaired and the cells will live. This
phenomenon is more prevalent in non-replicating or slowly
replicating cells, such as neurons in the brain, which cannot rely
on DNA repair mechanisms associated with DNA replication.
This is not a small problem. In humans, approximately 800 DNA
lesions occur per hour in each cell – about 19,200 per cell per day
[40]; and all pathways of DNA repair become less efficient with
age [41]. ATM expression goes down dramatically in aging tissues
[42] and is further reduced in AD frontal cortex compared to
controls (unpublished data). Our observations that expression of
both ATM and its downstream target, 53BP1, are substantially
lowered in cells deprived of glutamine suggest that low glutamine
supply may contribute to this phenomenon. Viewed in a
therapeutic light, however, the same data provide reason to
believe that glutamine supplementation may restore the aging
brain to a more youthful state when measured by the capability of
its stress responses.
Our data also show that glutamine deprivation reduces
autophagy under both basal and stressed conditions (Figure 4B).
This observation is consistent with a recent study showing that
glutamine increases autophagy under basal and stressed conditions
in intestinal epithelial cells [43]. In fact, autophagy and apoptosis
are positive stress responses of cells that ensure the health of cells
and organisms by replacing spent or damaged cellular components
[44]. Given the fact that autophagy in AD is reduced, we can
interpret these observations to mean that in this domain as well,
glutamine supplement will be beneficial to the AD patients.
While our findings underline the complexity of an organism’s
response to fluctuations in the levels of glutamine, they also
demonstrate that glutamine supplementation in vitro enables nerve
cells to resist stresses similar to those that affect the human brain
during the course of Alzheimer’s disease. More intriguing still is
our finding that glutamine supplementation may have a protective
effect on AD pathogenesis in vivo. Two different mouse models of
familial AD responded in positive ways to a relatively short (10-
day) nutritional supplement of glutamine in their drinking water.
The levels supplied were comparable to those used clinically in
human subjects and the strong interference with the neurodegen-
erative phenotype of induced neuronal cell cycle events and lost
synaptic markers suggests that this strategy might be a useful and
cost-effective adjunct to other therapeutic measures. In summary,
an optimal level of glutamine is important for aging neurons to
respond to stress. Our data provide strong support for the
protective effect of glutamine supplementation to avoid the
neurodegeneration of Alzheimer’s and other degenerative diseases.
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